We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
In the latest trading session, Pacific Biosciences of California (PACB - Free Report) closed at $1.62, marking a +2.53% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.51% for the day. On the other hand, the Dow registered a gain of 0.93%, and the technology-centric Nasdaq increased by 0.48%.
Prior to today's trading, shares of the maker of genetic analysis technology had gained 1.94% outpaced the Medical sector's loss of 3.38% and the S&P 500's gain of 0.74%.
The investment community will be paying close attention to the earnings performance of Pacific Biosciences of California in its upcoming release. The company is forecasted to report an EPS of -$0.13, showcasing a 8.33% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $37.86 million, down 1.51% from the year-ago period.
PACB's full-year Zacks Consensus Estimates are calling for earnings of -$0.43 per share and revenue of $156.1 million. These results would represent year-over-year changes of +18.87% and -2.44%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pacific Biosciences of California. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Pacific Biosciences of California is currently sporting a Zacks Rank of #4 (Sell).
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Pacific Biosciences of California (PACB - Free Report) closed at $1.62, marking a +2.53% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.51% for the day. On the other hand, the Dow registered a gain of 0.93%, and the technology-centric Nasdaq increased by 0.48%.
Prior to today's trading, shares of the maker of genetic analysis technology had gained 1.94% outpaced the Medical sector's loss of 3.38% and the S&P 500's gain of 0.74%.
The investment community will be paying close attention to the earnings performance of Pacific Biosciences of California in its upcoming release. The company is forecasted to report an EPS of -$0.13, showcasing a 8.33% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $37.86 million, down 1.51% from the year-ago period.
PACB's full-year Zacks Consensus Estimates are calling for earnings of -$0.43 per share and revenue of $156.1 million. These results would represent year-over-year changes of +18.87% and -2.44%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pacific Biosciences of California. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Pacific Biosciences of California is currently sporting a Zacks Rank of #4 (Sell).
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.